Agios Pharmaceuticals (AGIO) Receivables - Net (2014 - 2026)

Agios Pharmaceuticals (AGIO) has 12 years of Receivables - Net data on file, last reported at $24.2 million in Q2 2026.

• Quarterly Receivables - Net rose 385.68% year-over-year to $24.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $24.2 million (up 385.68% YoY) and the FY2025 annual result came in at $10.6 million, up 157.41% from the prior year.
• Receivables - Net improved to $24.2 million in Q2 2026, from $16.1 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $24.2 million in Q2 2026 to a low of $540000.0 in Q1 2022.
• A 5-year average of $5.2 million and a median of $3.2 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2023 — Receivables - Net plunged 35.31% — and 2026, when it jumped 385.68%.
• Tracing AGIO's Receivables - Net over 5 years: stood at $2.2 million in 2022, then increased by 27.38% to $2.8 million in 2023, then jumped by 46.23% to $4.1 million in 2024, then jumped by 157.41% to $10.6 million in 2025, then jumped by 128.95% to $24.2 million in 2026.
• The last three Receivables - Net figures came in at $24.2 million (Q2 2026), $16.1 million (Q1 2026), and $10.6 million (Q4 2025), per Business Quant data.